Longitudinal SARS-CoV-2 seroprevalence in Portugal and antibody maintenance 12 months after infection

Eur J Immunol. 2022 Jan;52(1):149-160. doi: 10.1002/eji.202149619. Epub 2021 Nov 10.

Abstract

During the COVID-19 pandemic, Portugal has experienced three distinct SARS-CoV-2 infection waves. We previously documented the prevalence of SARS-CoV-2 immunity, measured by specific antibodies, in September 2020, 6 months after the initial moderate wave. Here, we show the seroprevalence changes 6 months later, up to the second week of March 2021, shortly following the third wave, which was one of the most severe in the world, and 2 months following the start of the vaccination campaign. A longitudinal epidemiological study was conducted, with a stratified quota sample of the Portuguese population. Serological testing was performed, including ELISA determination of antibody class and titers. The proportion of seropositives, which was 2.2% in September 2020, rose sharply to 17.3% (95% CI: 15.8-18.8%) in March 2021. Importantly, circulating IgG and IgA antibody levels were very stable 6 months after the initial determination and up to a year after initial infection, indicating long-lasting infection immunity against SARS-CoV-2. Moreover, vaccinated people had higher IgG levels from 3 weeks post-vaccination when compared with previously infected people at the same time post-infection.

Keywords: COVID-19; antibodies; long-lasting immunity; longitudinal survey; vaccination.

Publication types

  • Observational Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Viral / immunology*
  • COVID-19 Serological Testing*
  • COVID-19* / epidemiology
  • COVID-19* / immunology
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoglobulin A / immunology*
  • Immunoglobulin G / immunology*
  • Male
  • Middle Aged
  • Portugal / epidemiology
  • Prevalence
  • SARS-CoV-2 / immunology*
  • Time Factors

Substances

  • Antibodies, Viral
  • Immunoglobulin A
  • Immunoglobulin G